Contamination Control and Data Integrity
Granules India received a warning letter from the USFDA in February 2025. This was along
Warning letters, 483s, Recalls, Import Alerts, Audit observations
Granules India received a warning letter from the USFDA in February 2025. This was along
USFDA inspected Granules India’s Finished Dosage and PFI facility (FEI 3004097901) at Gagillapur Village, Hyderabad
Cipla facility at Verna, Goa was audited by USFDA during June 2024 ending with issuance
USFDA 483 issued to Dr.Reddys (DRL) API unit in Pydibhimavaram, India cites failure to validate
Laurus Synthesis was issued an Untitled Letter by USFDA in May 2024, following critical observations
Laurus, Visakh was issued USFDA 483 with five (5) observations following USFDA inspection by investigators
Laurus, Visakh (India) was issued USFDA 483 with five (5) observations following USFDA inspection by
Laurus, Visakh was issued USFDA 483 with five (5) observations following USFDA inspection by investigators
USFDA inspected Laurus Synthesis, Visakh facility in India (FEI: 3011524794) in Dec 2023 by investigators